Primary cerebral malignant melanoma: A case report with literature review

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.1097/MD.0000000000005805</td>
</tr>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:31731777">http://nrs.harvard.edu/urn-3:HUL.InstRepos:31731777</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>
Primary cerebral malignant melanoma
A case report with literature review

Kai Tang, MD\textsuperscript{a}, Xiangyi Kong, MD\textsuperscript{b,c}, Gengsheng Mao, MD\textsuperscript{d}, Ming Qiu, MD\textsuperscript{d}, Haibo Zhu, MD\textsuperscript{d}, Lei Zhou, MD\textsuperscript{d}, Qingbin Nie, MD\textsuperscript{d}, Yi Xu, MD\textsuperscript{d}, Shiwei Du, MD\textsuperscript{e,}* 

Abstract
Primary intracranial melanomas are uncommon and constitute approximately 1% of all melanoma cases and 0.07% of all brain tumors. In nature, these primary melanomas are very aggressive and can spread to other organs.

We report an uncommon case of primary cerebral malignant melanoma—a challenging diagnosis guided by clinical presentations, radiological features, and surgical biopsy results, aiming to emphasize the importance of considering primary melanoma when making differential diagnoses of intracranial lesions.

We present a rare case of a primary cerebral melanoma in the left temporal lobe. The mass appeared iso-hypodense on brain computed tomography (CT), short signal on T1-weighted magnetic resonance images (T1WI) and long signal on T2WI. It was not easy to make an accurate diagnosis before surgery. We showed the patient’s disease course and reviewed related literatures, for readers’ reference. Written informed consent was obtained from the patient for publication of this case report and any accompanying images. Because of this, there is no need to conduct specific ethic review and the ethical approval is not necessary.

After surgery, the pathological examination confirmed the diagnosis of melanoma. The patient was discharged without any complications and went on to receive adjuvant radiochemotherapy.

It is difficult to diagnose primary cerebral melanoma in the absence of any cutaneous melanomas. A high index of clinical suspicion along with good pathology reporting is the key in diagnosing these extremely rare tumors.

Abbreviations: CK = cytokeratin, CNS = central nervous system, CPA = cerebellopontine angle, CT = computed tomography, GFAP = glial fibrillary acidic protein, HMB-45 = melanoma marker, IFN = interferon, MRI = magnetic resonance imaging, Olig 2 = oligodendrocyte transcription factor 2, PET = positron emission tomography, SRS = stereotactic radiosurgery, T1WI = T1-weighted image, T2WI = T2-weighted image, VEGF = vascular endothelial growth factor.

Keywords: case presentation, differential diagnosis, primary cerebral malignant melanoma

1. Introduction
In human beings, melanocyte exists in the uvea, cerebral parenchyma, leptomeninges, mucous membranes, and skin.\textsuperscript{[1]}

Malignant melanomas could originated from melanocytes, most of which are of cutaneous origins. Primary cerebral melanomas, derived from the melanocytic element normally present in the leptomeninges, are rare and occur in around 1% of all melanoma cases.\textsuperscript{[2,3]} Although preoperative anamnesis and computed tomography (CT) patterns are very similar to the presences of meningiomas or benign melanocytomas, these tumors show variable prognosis that depends on tumor site and extent of resection; therefore, to make an accurate diagnosis and identify the exact extent of the tumor area is important.\textsuperscript{[1]} Most patients with cerebral melanomas show clinical manifestation of increased intracerebral pressure (43%), neurological dysfunctions (35%), convulsion or subarachnoid hemorrhage (16%). Primary cerebral melanoma has a male dominance.\textsuperscript{[3]}

Since melanocytes exist in normal leptomeningeal tissues, it is not unexpected that primary melanomas could develop within the central nervous system (CNS). Nevertheless, mostly, melanomas involving CNS represent metastases. Primary cerebral melanomas were not reported commonly. They can spread to other systems and organs and are aggressive in nature. It is commonly a diagnosis of exclusion of metastatic disease based on an oral or skin or uveal melanoma by appropriate evaluations as brains are the most common sites for metastases from melanoma lung or breast. Generally, solitary intracranial lesions with no melanomatous lesions found outside the CNS could be primary melanomas. In order to achieve a desirable survival, the key treatment of choice for local intraparenchymal melanomas is complete resection plus radiochemotherapy.\textsuperscript{[4]} Temozolomide, as an effective chemotherapeutic medication, can cross blood brain barriers and exert cytotoxic effects on cancer cells in patients with
malignant melanoma. However once there are cancer spreads to leptomeninges, the overall median survival is generally only 10 weeks. We herein reported a case of the primary cerebral melanoma in the left temporal lobe, which was confirmed by histopathological examination of the excised mass. Also, related literatures were reviewed.

2. Case presentation

A 35-year-old woman presented with complaints of headache, nausea, and vomiting for 2 weeks. Her neurological examination was normal. He had no special previous history or family history. The results of routine blood chemical analysis and a complete blood count were normal.

CT scan showed a dural-based, extraaxial, well-defined, iso-hypodense area measuring around 5.1 cm × 4.2 cm × 3.5 cm (proved to be sludged blood by pathological examination afterwards) with an inside oval hyperdense lesion near the lateral border adjacent to the skull (proved to be a cystic lesion postoperatively, Fig. 1A and B). Irregular peritumoral vasogenic brain edema (hypodense) could be seen. Cerebral magnetic resonance imaging (MRI) with contrast revealed a mass in the left temporal area whose signal was short on T1-weighted image (T1WI) and long on T2WI. The peripheral cystic part mentioned above showed iso-long signal on T1WI and iso-short signal on T2WI, and was slightly enhanced after administration of gadolinium. The pathological field was surrounded by irregular edema (Fig. 1C–H). According to the CT and MRI features, a meningioma with intratumoral bleedings or a hemorrhagic metastasis was suspected.

A left frontotemporal craniotomy was performed, and at the dural opening, a large, blackish, vascular, firm tumor with multiple small satellite lesions in the arachnoid membrane was observed (Fig. 2A) and the main tumor was found to be embedded in the left temporal lobe along the sylvian fissure, with the brain acquiring a dark black coloration. Although the tumor was adherent to the arachnoid membrane and bled easily, the main tumor was separable from the brain parenchyma and grossly totally removed (Fig. 2B–F). Cerebrospinal fluid examinations did not reveal any evidences of malignant or atypical cells.

Pathohistological examinations confirmed the large part of sludged blood and the small part of cystic component, and revealed sheets of heavily pigmented cells with large nuclei and prominent nucleoli, consistent with malignant melanoma. The tumor was directly attached to the cerebral cortex but did not penetrate into the brain tissue. Immunohistochemistry showed a positive reaction for antimelanoma antibody (HMB-45), Melan A, S-100 protein, vascular endothelial growth factor (VEGF), glial fibrillary acidic protein (GFAP) and Vimentin, a partly positive reaction for oligodendrocyte transcription factor 2 (Olig 2) and CD68, and negative for cytokeratin (CK). The marker of proliferation Ki-67 was 3% positive staining. These findings were suggestive of a cerebral melanoma (Fig. 3).

Subsequent examinations, including dermatological physical examination and ophthalmologic fundoscopic examination, endoscopy of the gastrointestinal tract, body CT, and the positron emission tomography (PET) scan of the whole brain and body revealed no evidence of melanoma in other parts of the body.

The patient was discharged 5 days postoperatively without any complications and went on to receive adjuvant radiochemotherapy (concomitant stereotactic radiosurgery+temozolomide). For more than 11 months of follow-up, the patient recovered well without relevant sequelae or recurrences (Fig. 4).

3. Discussion

Melanomas originate from melanocytes, existing in the human uvea, cerebral parenchyma, leptomeninges, mucous membranes,
Figure 2. Intraoperative pictures showing the tumor was grossly removed completely. Although the tumor was adherent to the arachnoid membrane and bled easily, the main tumor was separable from the brain parenchyma and grossly totally removed.

Figure 3. Histopathological and immunohistochemical (IHC) examinations of the postsurgical specimen. (A) Hematein–Eosin staining. (B) HMB-45. (C) CD68. (D) Ki-67. (E) Melan A. (F) Oligo-2. (G) S-100 protein. (H) VEGF. (I) Vimentin.
Intracranial melanomas can be divided into metastatic type or primary type, and primary cerebral melanoma accounts for 1% of all melanomas. The literature quantity related to intracranial melanomas shows a tendency to increase year by year generally. On the basis of a world map for global distributions of intracranial-melanoma-related literatures according to the geolocational data analyses, the areas that the literatures come from concentrated mainly on Japan, Eastern United States and Europe (Fig. 5). Primary cerebral melanomas mainly derive from leptomeningeal melanocytes around the cervical cord or in the skull base. Metastatic melanomas presents mainly the features as followings: develop mainly in the elderly, whilst primary cerebral melanomas often develop in patients under 50 years of age and uncommonly metastasize to systemic organs; a poor and rapid clinical course because of possible systemic metastases; and multiple intracerebral tumors. Somers and his colleagues put forward that intracranial melanomas are more likely to be primary if there are no evidences of melanomas outside the CNS. Primary intracranial melanomas are classified as 4 different categories: melanosis of brain/spinal cord meninges correlated to cutaneous pigmentations (phakomatosis or neurocutaneous melanoses), primary cerebral isolated melanoma, discrete spinal-cord melanoma, and diffuse leptomeningeal melanomatoses. Our patient had no systemic melanomas detected by clinical examinations. Instead, only a solitary isolated mass was found. Regarding primary cerebral melanomas,
metastasis at 8-month follow-up. chemotherapy or radiotherapy and did not show recurrence or metastasis was present in 3 cases. Our case also received chemotherapy and radiotherapy. Five patients died within 1–2 years of operation or radiotherapy, presenting the effectiveness rate of chemotherapy drug is dacarbazine, which could be used after stereotaxic radiosurgery (SRS), alone or plus whole-brain radiotherapy, might improve lifespans of cerebral melanoma patients. Salpietro et al. put forward that specific immunotherapies were crucial adjuvant methods in treating small residual malignant melanomas, and presented low toxicities. High doses of interferon (IFN) β or IFN α-2b were found to be able to improve survival time and disease control, but the optimal dosages are still controversial. Humer et al. reported the bioremediation encountered by a patient (in remission for 2 years) with multiple melanoma metastases, but did not show intracranial metastatic lesions. With adjuvant radiotherapy and chemotherapy, the present patient is tumor free 8 months later and is still under follow-up.

### Table 1
Several histogenetic theories regarding primary cerebral melanomas.

<table>
<thead>
<tr>
<th>Theory</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mesodermal theory</td>
<td>The mesoderm gives rise to pigment cells that reach the brain or the spinal cord via the pial blood vessels</td>
</tr>
<tr>
<td>Ectodermal theory</td>
<td>Some epithelial cells produce pigment, and therefore, CNS melanomas are derived from the aberrant embryonic ectodermal cells</td>
</tr>
<tr>
<td>Neurontic theory</td>
<td>The pigment cells originate from the neural crest, which develop into mesodermal and neural elements</td>
</tr>
</tbody>
</table>

CNS = central nervous system.

although origins of melanin cells are still not fully unveiled, some histogenetic hypotheses were put forward by scholars (Table 1). Suranagi et al. once reviewed 19 cases reported over a period of 25 years. Male predominance was noted. The tumor was frequently observed in the middle age to elderly age group. Most of the cases involved different areas of the cerebrum except for 3 cases occurring in the cerebellopontine angle (CPA). The presenting symptoms were headache, oculomotor palsy, and seizures. Six patients showed recurrence mostly within 18 months, except in 1 case where the tumor recurred after 23 years. Excision of the tumor was possible in a total of 14 cases; while others were given adjuvant chemotherapy or radiotherapy. Five patients died within 1–2 years of operation or radiotherapy, presenting the effectiveness rate of chemotherapy drug is dacarbazine, which could be used after stereotaxic radiosurgery (SRS), alone or plus whole-brain radiotherapy, might improve lifespans of cerebral melanoma patients. Salpietro et al. put forward that specific immunotherapies were crucial adjuvant methods in treating small residual malignant melanomas, and presented low toxicities. High doses of interferon (IFN) β or IFN α-2b were found to be able to improve survival time and disease control, but the optimal dosages are still controversial. Humer et al. reported the bioremediation encountered by a patient (in remission for 2 years) with multiple melanoma metastases, but did not show intracranial metastatic lesions. With adjuvant radiotherapy and chemotherapy, the present patient is tumor free 8 months later and is still under follow-up.

### Table 2
Other differential diagnoses besides metastatic cerebral melanomas.

<table>
<thead>
<tr>
<th>Tumors</th>
<th>Features for different diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meningeal melanocytoma</td>
<td>A rare benign melanotic neoplasm that derives from meningeal melanocytes. Generally the tumor is a single blackish nodular mass. In the literature, rare mitotic figures and no necrotic or hemorrhagic areas are described</td>
</tr>
<tr>
<td>Leptomeningeal melanosis</td>
<td>Benign pia-arachnoid hyperpigmentation of the brain or spinal cord. This condition is generally asymptomatic. This finding may be familial and associated with cutaneous nevi</td>
</tr>
<tr>
<td>Meningioma</td>
<td>Meningioma may have similar neuroradiologic findings and may mimic cerebral melanoma (hyperdense enhancing lesion on CT, in contact with the skull and dura mater). The differential diagnosis is more difficult in some cases of meningioma with cells containing melanin pigment or of ectopic meningioma</td>
</tr>
</tbody>
</table>

CT = computed tomography.
4. Conclusion

It is difficult to diagnose primary cerebral melanoma in the absence of any cutaneous melanosis. A high index of clinical suspicion along with good pathology reporting is the key in diagnosing these extremely rare tumors. The roles of adjuvant radiochemotherapy have not been well-established. Improvements in targeted therapies, immunotherapies, and chemotherapy might provide more efficient treatments for primary cerebral melanomas.

References